MIMETAS is launching a standardized contract research offering called OrganoServices, which provides compound and study requirements, runs experiments on the OrganoPlate platform using validated OrganoReady models, and receives a structured results report.

We strive to contribute to groundbreaking therapies with our screenable, physiologically relevant 3D human disease models. By combining technological strengths and expertise, we establish strong drug development partnerships with and offer services to global pharmaceutical companies to develop innovative therapies to target untreatable diseases. For more information, visit: www.mimetas.com.